Background Successful mass vaccination programmes are public health achievements of
the contemporary world. While pharmaceutical companies are actively developing new …

For the longest time, the field of nucleic acid delivery has remained skeptical whether or not
polycationic drug carrier systems would ever make it into clinical practice. Yet, with the …

Abstract Background Coronavirus-like particles (CoVLP) that are produced in plants and
display the prefusion spike glycoprotein of the original strain of severe acute respiratory …

The ongoing coronavirus disease 2019 (COVID‐19) pandemic, caused by severe acute
respiratory coronavirus 2 (SARS‐CoV‐2), has killed untold millions worldwide and has …

Along with the global spread of the COVID-19 pandemic, a number of hospitals are
operating in the over-loaded state, which results in the ever-increasing requirements of …

Introduction Injected mRNA vaccines have been proven effective and safe in the SARS-CoV-
2 pandemic. Using the machinery of the cell, mRNA vaccines translate into an antigen …

The inability of many biopharmaceutical formulations to retain their structure and integrity
when in solution represents a major issue for their transport and storage, reducing their shelf …

The purpose of this research is to develop a new type of core/wall material reinforced
microcapsules by in-situ polymerization, which is applied to polyurethane foam (PUF) to …

Vaccination is one of the most efficient ways to restrict and control the spread of epidemic
outbreaks such as COVID-19. Due to the limited COVID-19 vaccine supply, an equitable and …

AS01 B is a liposomal formulation of two immunostimulants namely 3-O-desacyl-4́-
monophosphoryl lipid A (MPL) and QS-21. The liposomal formulation of AS01 B reduces the …